Justin T Okano1, Danielle Robbins1, Laurence Palk1, Jan Gerstoft2, Niels Obel2, Sally Blower3. 1. Center for Biomedical Modelling, Semel Institute for Neuroscience and Human Behaviour, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 2. Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. 3. Center for Biomedical Modelling, Semel Institute for Neuroscience and Human Behaviour, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: sblower@mednet.ucla.edu.
Abstract
BACKGROUND: Worldwide, approximately 35 million individuals are infected with HIV; about 25 million of these live in sub-Saharan Africa. WHO proposes using treatment as prevention (TasP) to eliminate HIV. Treatment suppresses viral load, decreasing the probability an individual transmits HIV. The elimination threshold is one new HIV infection per 1000 individuals. Here, we test the hypothesis that TasP can substantially reduce epidemics and eliminate HIV. We estimate the impact of TasP, between 1996 and 2013, on the Danish HIV epidemic in men who have sex with men (MSM), an epidemic UNAIDS has identified as a priority for elimination. METHODS: We use a CD4-staged Bayesian back-calculation approach to estimate incidence, and the hidden epidemic (the number of HIV-infected undiagnosed MSM). To develop the back-calculation model, we use data from an ongoing nationwide population-based study: the Danish HIV Cohort Study. FINDINGS: Incidence, and the hidden epidemic, decreased substantially after treatment was introduced in 1996. By 2013, incidence was close to the elimination threshold: 1·4 (median, 95% Bayesian credible interval [BCI] 0·4-2·1) new HIV infections per 1000 MSM and there were only 617 (264-858) undiagnosed MSM. Decreasing incidence and increasing treatment coverage were highly correlated; a treatment threshold effect was apparent. INTERPRETATION: Our study is the first to show that TasP can substantially reduce a country's HIV epidemic, and bring it close to elimination. However, we have shown the effectiveness of TasP under optimal conditions: very high treatment coverage, and exceptionally high (98%) viral suppression rate. Unless these extremely challenging conditions can be met in sub-Saharan Africa, the WHO's global elimination strategy is unlikely to succeed. FUNDING: National Institute of Allergy and Infectious Diseases.
BACKGROUND: Worldwide, approximately 35 million individuals are infected with HIV; about 25 million of these live in sub-Saharan Africa. WHO proposes using treatment as prevention (TasP) to eliminate HIV. Treatment suppresses viral load, decreasing the probability an individual transmits HIV. The elimination threshold is one new HIV infection per 1000 individuals. Here, we test the hypothesis that TasP can substantially reduce epidemics and eliminate HIV. We estimate the impact of TasP, between 1996 and 2013, on the Danish HIV epidemic in men who have sex with men (MSM), an epidemic UNAIDS has identified as a priority for elimination. METHODS: We use a CD4-staged Bayesian back-calculation approach to estimate incidence, and the hidden epidemic (the number of HIV-infected undiagnosed MSM). To develop the back-calculation model, we use data from an ongoing nationwide population-based study: the Danish HIV Cohort Study. FINDINGS: Incidence, and the hidden epidemic, decreased substantially after treatment was introduced in 1996. By 2013, incidence was close to the elimination threshold: 1·4 (median, 95% Bayesian credible interval [BCI] 0·4-2·1) new HIV infections per 1000 MSM and there were only 617 (264-858) undiagnosed MSM. Decreasing incidence and increasing treatment coverage were highly correlated; a treatment threshold effect was apparent. INTERPRETATION: Our study is the first to show that TasP can substantially reduce a country's HIV epidemic, and bring it close to elimination. However, we have shown the effectiveness of TasP under optimal conditions: very high treatment coverage, and exceptionally high (98%) viral suppression rate. Unless these extremely challenging conditions can be met in sub-Saharan Africa, the WHO's global elimination strategy is unlikely to succeed. FUNDING: National Institute of Allergy and Infectious Diseases.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Qiuying Yang; David Boulos; Ping Yan; Fan Zhang; Robert S Remis; Dena Schanzer; Chris P Archibald Journal: Can J Public Health Date: 2010 Nov-Dec
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Moupali Das; Priscilla Lee Chu; Glenn-Milo Santos; Susan Scheer; Eric Vittinghoff; Willi McFarland; Grant N Colfax Journal: PLoS One Date: 2010-06-10 Impact factor: 3.240
Authors: Paul J Birrell; O Noel Gill; Valerie C Delpech; Alison E Brown; Sarika Desai; Tim R Chadborn; Brian D Rice; Daniela De Angelis Journal: Lancet Infect Dis Date: 2013-02-01 Impact factor: 25.071
Authors: Andrew N Phillips; Valentina Cambiano; Fumiyo Nakagawa; Alison E Brown; Fiona Lampe; Alison Rodger; Alec Miners; Jonathan Elford; Graham Hart; Anne M Johnson; Jens Lundgren; Valerie C Delpech Journal: PLoS One Date: 2013-02-15 Impact factor: 3.240
Authors: Long Hoang Nguyen; Bach Xuan Tran; Luis E C Rocha; Huong Lan Thi Nguyen; Cui Yang; Carl A Latkin; Anna Thorson; Susanne Strömdahl Journal: AIDS Behav Date: 2019-09
Authors: Dawn K Smith; Patrick S Sullivan; Betsy Cadwell; Lance A Waller; Azfar Siddiqi; Robertino Mera-Giler; Xiaohong Hu; Karen W Hoover; Norma S Harris; Scott McCallister Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079
Authors: Juliana Maria Reyes-Urueña; Colin N J Campbell; Núria Vives; Anna Esteve; Juan Ambrosioni; Cristina Tural; Elena Ferrer; Gemma Navarro; Lluis Force; Isabel García; Àngels Masabeu; Josep M Vilaró; Patricia García de Olalla; Joan Artur Caylà; Josep M Miró; Jordi Casabona Journal: BMJ Open Date: 2018-02-28 Impact factor: 2.692
Authors: M Kate Grabowski; David M Serwadda; Ronald H Gray; Gertrude Nakigozi; Godfrey Kigozi; Joseph Kagaayi; Robert Ssekubugu; Fred Nalugoda; Justin Lessler; Thomas Lutalo; Ronald M Galiwango; Fred Makumbi; Xiangrong Kong; Donna Kabatesi; Stella T Alamo; Steven Wiersma; Nelson K Sewankambo; Aaron A R Tobian; Oliver Laeyendecker; Thomas C Quinn; Steven J Reynolds; Maria J Wawer; Larry W Chang Journal: N Engl J Med Date: 2017-11-30 Impact factor: 91.245
Authors: D Callander; M Stoové; A Carr; J F Hoy; K Petoumenos; M Hellard; J Elliot; D J Templeton; S Liaw; D P Wilson; A Grulich; D A Cooper; A Pedrana; B Donovan; J McMahon; G Prestage; M Holt; C K Fairley; N McKellar-Stewart; S Ruth; J Asselin; P Keen; C Cooper; B Allan; J M Kaldor; R Guy Journal: BMC Infect Dis Date: 2016-12-12 Impact factor: 3.090